PharmiWeb.com - Global Pharma News & Resources
30-Aug-2018

GenesisCare invests £12 million to double cutting-edge cancer care services in Oxfordshire

GenesisCare is excited to announce that building work has started on a £12million expansion to create a state-of-the-art cancer imaging and treatment centre; GenesisCare, Oxford. This investment into local healthcare services in Oxfordshire will allow an additional 1,000 people suffering with cancer to receive world-class cancer care closer to home. 

 

The investment comes after four successful years of GenesisCare services in Oxford, doubling the footprint of the original site at Eastpoint Business Park, providing greater patient access and 15 new permanent jobs. This will enable the centre to offer the latest in cancer imaging and radiotherapy care, including the addition of advanced PET-CT and 3T MRI imaging machines. This will help reduce patient waiting times and the need to travel long distances to other areas of the county in order to access the latest cancer care. The new facilities and services will allow patients to be referred, diagnosed and treated on average in 5 days – providing patients with high quality care, speed of access and control over their treatment pathway. 

 

Dr Ruth MacPherson, Consultant Radiologist said, “The latest in MRI and PET-CT imaging systems are central to the management of cancer patients. This investment in sophisticated, state of the art services will enable patients presenting with suspected cancer to receive a rapid and accurate diagnosis, whilst those receiving therapy will have their treatment responses monitored with greater precision.” 

 

By December 2018 the expansion will also include a new theranostic suite and clinical trials unit which will provide research academic institutions and industry partners new options to conduct clinical trials in a dedicated environment in which to further cancer research in a world leading setting. The theranostics service will offer a highly personalised and targeted form of radiation therapy that is not available in Oxford, and not widely available in the UK and Europe. 

 

Aldo Rolfo, GenesisCare General Manager – UK said: “We are really pleased to be expanding our Oxford site. It will offer the very best cancer care for the Oxford and neighbouring communities with world leading clinicians and technology. We pride ourselves on offering rapid access to services, individually tailored treatment programmes using the best technology and living well care experiences that provide the best possible life outcomes.”